title: Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation.
abstract: OBJECTIVE
  It is presently unknown whether patients with atrial fibrillation (AF) are at increased risk of thrombo-embolic adverse events after interruption of warfarin treatment. The purpose of this study was to assess the risk and timing of thrombo-embolism after warfarin treatment interruption.
  
  
  RESULTS
  A retrospective, nationwide cohort study of all patients in Denmark treated with warfarin after a first hospitalization with AF in the period 1997-2008. Incidence rate ratios (IRRs) of thrombo-embolic events and all-cause mortality were calculated using the Poisson regression analyses. In total, 48 989 AF patients receiving warfarin treatment were included. Of these, 35 396 patients had at least one episode of warfarin treatment interruption. In all, 8255 deaths or thrombo-embolic events occurred during treatment interruption showing an initial clustering of events with 2717, 835, 500, and 427 events occurring during 0-90, 91-180, 181-270, and 271-360 days after treatment interruption, respectively. Correspondingly, the crude incidence rates were 31.6, 17.7, 12.3, and 11.4 events per 100 patient-years. In a multivariable analysis, the first 90-day interval of treatment interruption was associated with a markedly higher risk of death or thrombo-embolism (IRR 2.5; 95% confidence interval 2.3-2.8) vs. the interval of 271-360 days.
  
  
  CONCLUSIONS
  In patients with AF, an interruption of warfarin treatment is associated with a significantly increased short-term risk of death or thrombo-embolic events within the first 90 days of treatment interruption.
authors.affiliation: Department of Cardiology, Copenhagen University Hospital Gentofte, Post 67, Hellerup 2900, Denmark. jrj@heart.dk
authors.forename: Jakob
authors.initials: J
authors.lastname: Raunsø
authors.forename: Christian
authors.initials: C
authors.lastname: Selmer
authors.forename: Jonas Bjerring
authors.initials: JB
authors.lastname: Olesen
authors.forename: Mette Gitz
authors.initials: MG
authors.lastname: Charlot
authors.forename: Anne-Marie S
authors.initials: AM
authors.lastname: Olsen
authors.forename: Ditte-Marie
authors.initials: DM
authors.lastname: Bretler
authors.forename: Jørn Dalsgaard
authors.initials: JD
authors.lastname: Nielsen
authors.forename: Helena
authors.initials: H
authors.lastname: Dominguez
authors.forename: Niels
authors.initials: N
authors.lastname: Gadsbøll
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Gislason
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.forename: Morten Lock
authors.initials: ML
authors.lastname: Hansen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002423:Cause of Death; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology* / Q000401:mortality*; D014859:Warfarin / Q000627:therapeutic use*; D028761:Withholding Treatment
chemical_list: D000925:Anticoagulants; D014859:Warfarin